Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
RLYB Rallybio
13.600
+0.340+2.56%
Post Mkt Price
13.60000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Investing cash flow
Cash flow from continuing investing activities
-373.27% -7.12M -14166.55% -80.18M -12.6% -2.33M 69.96% -137K
Net PPE purchase and sale
-250% -14K 41.94% -36K -143.07% -333K -29.25% -137K
Net business purchase and sale
90% -150K -- 0 -3.36% -2M -- 0
Net investment purchase and sale
-- -6.95M -- -80.14M -- -- -- --
Cash from discontinued investing activities
Investing cash flow
-373.27% -7.12M -14166.55% -80.18M -12.6% -2.33M 69.96% -137K
Financing cash flow
Cash flow from continuing financing activities
-42.74% 82.97M -16110% -1.62M
Net common stock issuance
-- -- -- -- -40.64% 86.2M -- 0
Net other financing activities
-- -- -- -- -913.48% -3.23M -16110% -1.62M
Cash from discontinued financing activities
Financing cash flow
-- 0 -- 0 -42.74% 82.97M -16110% -1.62M
Net cash flow
Beginning cash position
-36.26% 81.43M 25.03% 175.33M 620.7% 140.23M 26.37% 186.98M
Current changes in cash
-37.69% -20.67M -651.81% -93.91M -70.94% 35.1M -50.69% -11.64M
End cash Position
-46.11% 60.75M -36.26% 81.43M 25.03% 175.33M 25.03% 175.33M
Free cash flow
-5.59% -13.57M -14.81% -13.77M -106.83% -45.87M -36.05% -10.02M
Investing cash flow
Cash flow from continuing investing activities
-373.27% -7.12M -14166.55% -80.18M -12.6% -2.33M 69.96% -137K
Net PPE purchase and sale
-250% -14K 41.94% -36K -143.07% -333K -29.25% -137K
Net business purchase and sale
90% -150K -- 0 -3.36% -2M -- 0
Net investment purchase and sale
-- -6.95M -- -80.14M -- -- -- --
Cash from discontinued investing activities
Investing cash flow
-373.27% -7.12M -14166.55% -80.18M -12.6% -2.33M 69.96% -137K
Financing cash flow
Cash flow from continuing financing activities
-42.74% 82.97M -16110% -1.62M
Net common stock issuance
-- -- -- -- -40.64% 86.2M -- 0
Net other financing activities
-- -- -- -- -913.48% -3.23M -16110% -1.62M
Cash from discontinued financing activities
Financing cash flow
-- 0 -- 0 -42.74% 82.97M -16110% -1.62M
Net cash flow
Beginning cash position
-36.26% 81.43M 25.03% 175.33M 620.7% 140.23M 26.37% 186.98M
Current changes in cash
-37.69% -20.67M -651.81% -93.91M -70.94% 35.1M -50.69% -11.64M
End cash Position
-46.11% 60.75M -36.26% 81.43M 25.03% 175.33M 25.03% 175.33M
Free cash flow
-5.59% -13.57M -14.81% -13.77M -106.83% -45.87M -36.05% -10.02M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
CEO: MacKay Ph.D., Martin W.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top